Monique Spillman
Title | Professor |
---|
Institution | University of Arkansas for Medical Sciences |
---|
Department | COM | Obstetrics & Gynecology |
---|
Address | 4301 W Markham Little Rock AR 72205
|
---|
vCard | Download vCard |
---|
|
|
|
Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
Faculty can login to make corrections and additions.
Don't see publications published under other names? Login to add alternative names.
-
Buckley DN, Lewinger JP, Gooden G, Spillman M, Neuman M, Guo XM, Tew BY, Miller H, Khetan VU, Shulman LP, Roman L, Salhia B. OvaPrint-A Cell-free DNA Methylation Liquid Biopsy for the Risk Assessment of High-grade Serous Ovarian Cancer. Clin Cancer Res. 2023 12 15; 29(24):5196-5206. PMID: 37812492.
-
Brown AJ, duPont N, Alvarez RD, Spillman MA, Landrum L, Lefkowits C. MAID ready for primetime?: A survey of SGO members regarding medical aid in dying (MAID). Gynecol Oncol Rep. 2021 Aug; 37:100829. PMID: 34277920.
-
Kandimalla R, Wang W, Yu F, Zhou N, Gao F, Spillman M, Moukova L, Slaby O, Salhia B, Zhou S, Wang X, Goel A. OCaMIR-A Noninvasive, Diagnostic Signature for Early-Stage Ovarian Cancer: A Multi-cohort Retrospective and Prospective Study. Clin Cancer Res. 2021 08 01; 27(15):4277-4286. PMID: 34035068.
-
Shalowitz DI, Lefkowits C, Landrum LM, von Gruenigen VE, Spillman MA. Principles of ethics and critical communication during the COVID-19 pandemic. Gynecol Oncol. 2020 09; 158(3):526-530. PMID: 32622474.
-
Adams CL, Dimitrova I, Post MD, Gibson L, Spillman MA, Behbakht K, Bradford AP. Identification of a novel diagnostic gene expression signature to discriminate uterine leiomyoma from leiomyosarcoma. Exp Mol Pathol. 2019 10; 110:104284. PMID: 31301306.
-
Wheeler LJ, Watson ZL, Qamar L, Yamamoto TM, Post MD, Berning AA, Spillman MA, Behbakht K, Bitler BG. CBX2 identified as driver of anoikis escape and dissemination in high grade serous ovarian cancer. Oncogenesis. 2018 Nov 26; 7(11):92. PMID: 30478317.
-
Spillman MA, Sade RM. A Woman in Full. Am J Bioeth. 2018 07; 18(7):32-34. PMID: 30040572.
-
Richmond AM, Blake EA, Torkko K, Smith EE, Spillman MA, Post MD. Fascin Is Associated With Aggressive Behavior and Poor Outcome in Uterine Carcinosarcoma. Int J Gynecol Cancer. 2017 11; 27(9):1895-1903. PMID: 28704324.
-
Zhou K, Diebel KW, Holy J, Skildum A, Odean E, Hicks DA, Schotl B, Abrahante JE, Spillman MA, Bemis LT. A tRNA fragment, tRF5-Glu, regulates BCAR3 expression and proliferation in ovarian cancer cells. Oncotarget. 2017 Nov 10; 8(56):95377-95391. PMID: 29221134.
-
Zhou K, Spillman MA, Behbakht K, Komatsu JM, Abrahante JE, Hicks D, Schotl B, Odean E, Jones KL, Graner MW, Bemis LT. A method for extracting and characterizing RNA from urine: For downstream PCR and RNAseq analysis. Anal Biochem. 2017 11 01; 536:8-15. PMID: 28803886.
-
Hicks DA, Galimanis CE, Webb PG, Spillman MA, Behbakht K, Neville MC, Baumgartner HK. Claudin-4 activity in ovarian tumor cell apoptosis resistance and migration. BMC Cancer. 2016 10 11; 16(1):788. PMID: 27724921.
-
Shalowitz DI, Spillman MA, Morgan MA. Reply. Am J Obstet Gynecol. 2016 12; 215(6):811. PMID: 27496688.
-
Shalowitz DI, Spillman MA, Morgan MA. Interactions with industry under the Sunshine Act: an?example from gynecologic oncology. Am J Obstet Gynecol. 2016 06; 214(6):703-7. PMID: 26902988.
-
Guy MS, Qamar L, Behbakht K, Post MD, Sheeder J, Sartorius CA, Spillman MA. Progestin treatment decreases CD133+ cancer stem cell populations in endometrial cancer. Gynecol Oncol. 2016 Mar; 140(3):518-26. PMID: 26731726.
-
Corr BR, Finlay-Schultz J, Rosen RB, Qamar L, Post MD, Behbakht K, Spillman MA, Sartorius CA. Cytokeratin 5-Positive Cells Represent a Therapy Resistant subpopulation in Epithelial Ovarian Cancer. Int J Gynecol Cancer. 2015 Nov; 25(9):1565-73. PMID: 26495758.
-
Enriquez VA, Cleys ER, Da Silveira JC, Spillman MA, Winger QA, Bouma GJ. High LIN28A Expressing Ovarian Cancer Cells Secrete Exosomes That Induce Invasion and Migration in HEK293 Cells. Biomed Res Int. 2015; 2015:701390. PMID: 26583126.
-
Arora KS, Spillman M, Milad M. Bits and pieces: the ethics of uterine morcellation. Obstet Gynecol. 2014 Dec; 124(6):1199-1201. PMID: 25415172.
-
Spillman MA, Sade RM. I, robotic surgeon. Virtual Mentor. 2014 Oct 01; 16(10):813-7. PMID: 25310049.
-
Powell MA, Sill MW, Goodfellow PJ, Benbrook DM, Lankes HA, Leslie KK, Jeske Y, Mannel RS, Spillman MA, Lee PS, Hoffman JS, McMeekin DS, Pollock PM. A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2014 Oct; 135(1):38-43. PMID: 25019571.
-
Hopkins MR, Richmond AM, Cheng G, Davidson S, Spillman MA, Sheeder J, Post MD, Guntupalli SR. Lymphovascular space invasion in robotic surgery for endometrial cancer. JSLS. 2014 Jul-Sep; 18(3). PMID: 25392608.
-
Guy MS, Cheng G, Post MD, Spillman MA, Behbakht K, Davidson S, Sheeder J, Guntupalli SR. Outcomes of women with atypical glandular cells on preoperative cytology and endometrial cancer. Int J Gynecol Cancer. 2014 Feb; 24(2):266-71. PMID: 24401985.
-
Corr BR, Behbakht K, Spillman MA. Gynecologic biopsy for molecular profiling: a review for the interventional radiologist. Semin Intervent Radiol. 2013 Dec; 30(4):417-24. PMID: 24436571.
-
Anglesio MS, Wiegand KC, Melnyk N, Chow C, Salamanca C, Prentice LM, Senz J, Yang W, Spillman MA, Cochrane DR, Shumansky K, Shah SP, Kalloger SE, Huntsman DG. Correction: Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research. PLoS One. 2013; 8(9). PMID: 24116245.
-
Anglesio MS, Wiegand KC, Melnyk N, Chow C, Salamanca C, Prentice LM, Senz J, Yang W, Spillman MA, Cochrane DR, Shumansky K, Shah SP, Kalloger SE, Huntsman DG. Type-specific cell line models for type-specific ovarian cancer research. PLoS One. 2013; 8(9):e72162. PMID: 24023729.
-
Pedersen BS, Konstantinopoulos PA, Spillman MA, De S. Copy neutral loss of heterozygosity is more frequent in older ovarian cancer patients. Genes Chromosomes Cancer. 2013 Sep; 52(9):794-801. PMID: 23716468.
-
Alvarez RD, Gray HJ, Timmins PF, Gibb RK, Edelson M, Fowler JM, Havrilesky LJ, McCauley DL, Nash JD, Rahaman J, Rash JK, Rodabaugh KJ, Powell MA, Bristow RE, Brown JV, Tewari D, Cliby WA, Anastasia P, Robinson WR, Shahin MS, Cantrell LA, Cloven NG, Gold MA, Hope JM, Muntz HG, Sorosky JI, Elkas JC, Frumovitz MM, Jewell E, Spillman MA, Naumann RW. We need a new paradigm in gynecologic cancer care: SGO proposes solutions for delivery, quality and reimbursement policies. Gynecol Oncol. 2013 Apr; 129(1):3-4. PMID: 23638463.
-
Webb PG, Spillman MA, Baumgartner HK. Claudins play a role in normal and tumor cell motility. BMC Cell Biol. 2013 Mar 23; 14:19. PMID: 23521713.
-
Anderson CK, Wallace S, Guiahi M, Sheeder J, Behbakht K, Spillman MA. Risk-reducing salpingectomy as preventative strategy for pelvic serous cancer. Int J Gynecol Cancer. 2013 Mar; 23(3):417-21. PMID: 23385282.
-
Jambal P, Badtke MM, Harrell JC, Borges VF, Post MD, Sollender GE, Spillman MA, Horwitz KB, Jacobsen BM. Estrogen switches pure mucinous breast cancer to invasive lobular carcinoma with mucinous features. Breast Cancer Res Treat. 2013 Jan; 137(2):431-48. PMID: 23247610.
-
Cittelly DM, Dimitrova I, Howe EN, Cochrane DR, Jean A, Spoelstra NS, Post MD, Lu X, Broaddus RR, Spillman MA, Richer JK. Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel. Mol Cancer Ther. 2012 Dec; 11(12):2556-65. PMID: 23074172.
-
Korch C, Spillman MA, Jackson TA, Jacobsen BM, Murphy SK, Lessey BA, Jordan VC, Bradford AP. DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination. Gynecol Oncol. 2012 Oct; 127(1):241-8. PMID: 22710073.
-
Qamar L, Deitsch E, Patrick AN, Post MD, Spillman MA, Iwanaga R, Thorburn A, Ford HL, Behbakht K. Specificity and prognostic validation of a polyclonal antibody to detect Six1 homeoprotein in ovarian cancer. Gynecol Oncol. 2012 May; 125(2):451-7. PMID: 22333994.
-
Ralston SJ, Spillman MA, Mitchell MF, Mahoney J, Joseph GF. Obstetricians: women's advocates, not adversaries. Am J Bioeth. 2011 Dec; 11(12):57-9. PMID: 22146036.
-
Stashwick C, Post MD, Arruda JS, Spillman MA, Behbakht K, Davidson SA, Kelly MG. Surgical risk score predicts suboptimal debulking or a major perioperative complication in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. Int J Gynecol Cancer. 2011 Nov; 21(8):1422-7. PMID: 21997170.
-
Spillman MA. Until debt do us part. Gynecol Oncol. 2011 Dec; 123(3):455. PMID: 22020038.
-
Spillman MA, Sade R. Does fortune foul fidelity? Am J Bioeth. 2011 Sep; 11(9):14-5. PMID: 21877965.
-
Badtke MM, Jambal P, Dye WW, Spillman MA, Post MD, Horwitz KB, Jacobsen BM. Unliganded progesterone receptors attenuate taxane-induced breast cancer cell death by modulating the spindle assembly checkpoint. Breast Cancer Res Treat. 2012 Jan; 131(1):75-87. PMID: 21340479.
-
Embry JR, Kelly MG, Post MD, Spillman MA. Large cell neuroendocrine carcinoma of the cervix: prognostic factors and survival advantage with platinum chemotherapy. Gynecol Oncol. 2011 Mar; 120(3):444-8. PMID: 21138780.
-
Spillman MA, Manning NG, Dye WW, Sartorius CA, Post MD, Harrell JC, Jacobsen BM, Horwitz KB. Tissue-specific pathways for estrogen regulation of ovarian cancer growth and metastasis. Cancer Res. 2010 Nov 01; 70(21):8927-36. PMID: 20959477.
-
Spillman MA. SGO Washington Update: the price of a profession. Gynecol Oncol. 2010 Oct; 119(1):3-4. PMID: 20708785.
-
Lange CA, Sartorius CA, Abdel-Hafiz H, Spillman MA, Horwitz KB, Jacobsen BM. Progesterone receptor action: translating studies in breast cancer models to clinical insights. Adv Exp Med Biol. 2008; 630:94-111. PMID: 18637487.
-
Spillman MA, Lacy J, Murphy SK, Whitaker RS, Grace L, Teaberry V, Marks JR, Berchuck A. Regulation of the metastasis suppressor gene MKK4 in ovarian cancer. Gynecol Oncol. 2007 May; 105(2):312-20. PMID: 17276500.
-
Spillman MA, Sade RM. Clinical trials of xenotransplantation: waiver of the right to withdraw from a clinical trial should be required. J Law Med Ethics. 2007; 35(2):265-72. PMID: 17518852.
-
Murphy SK, Huang Z, Wen Y, Spillman MA, Whitaker RS, Simel LR, Nichols TD, Marks JR, Berchuck A. Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer. Mol Cancer Res. 2006 Apr; 4(4):283-92. PMID: 16603642.
-
Spillman MA, Schildkraut JM, Halabi S, Moorman P, Calingaert B, Bentley RC, Marks JR, Murphy S, Berchuck A. Transforming growth factor beta receptor I polyalanine repeat polymorphism does not increase ovarian cancer risk. Gynecol Oncol. 2005 May; 97(2):543-9. PMID: 15863158.
-
Spillman MA, Berchuck A. Stretching the surface epithelium. J Soc Gynecol Investig. 2004 Dec; 11(8):501-2. PMID: 15582493.
-
Taub S, Morin K, Sade RM, Spillman MA. Safeguards in the use of DNA databanks in genomic research. Genet Med. 2004 Nov-Dec; 6(6):526-9. PMID: 15545750.
-
Taub S, Morin K, Spillman MA, Sade RM, Riddick FA. Managing familial risk in genetic testing. Genet Test. 2004; 8(3):356-9. PMID: 15727262.
-
Morin K, Rakatansky H, Riddick FA, Morse LJ, O'Bannon JM, Goldrich MS, Ray P, Weiss M, Sade RM, Spillman MA. Managing conflicts of interest in the conduct of clinical trials. JAMA. 2002 Jan 02; 287(1):78-84. PMID: 11754712.
This graph shows the total number of publications by year, by first, middle/unknown, or last author.
To see the data from this visualization as text, click here.
Year | Publications |
---|
2002 | 1 | 2004 | 3 | 2005 | 1 | 2006 | 1 | 2007 | 2 | 2008 | 1 | 2010 | 3 | 2011 | 5 | 2012 | 4 | 2013 | 7 | 2014 | 5 | 2015 | 3 | 2016 | 3 | 2017 | 3 | 2018 | 2 | 2019 | 1 | 2020 | 1 | 2021 | 2 | 2023 | 1 |
To return to the timeline, click here.
|
Spillman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Similar People People who share similar concepts with this person. _
|